Araim Pharmaceuticals (United States)

Recent papers from Araim Pharmaceuticals (United States)

1. A small erythropoietin derived non-hematopoietic peptide reduces cardiac inflammation, attenuates age associated declines in heart function and prolongs healthspanFrontiers in Cardiovascular Medicine · 2023
2. The erythropoietin‐derived peptide ARA 284 reduces tissue wasting and improves survival in a rat model of cancer cachexiaJournal of Cachexia Sarcopenia and Muscle · 2022
3. The Non-Erythropoietic EPO Analogue Cibinetide Inhibits Osteoclastogenesis In Vitro and Increases Bone Mineral Density in MiceInternational Journal of Molecular Sciences · 2021
4. Cibinetide Protects Isolated Human Islets in a Stressful Environment and Improves Engraftment in the Perspective of Intra Portal Islet TransplantationCell Transplantation · 2021
5. A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular EdemaJournal of Clinical Medicine · 2020
6. Improvement of Islet Allograft Function Using Cibinetide, an Innate Repair Receptor LigandTransplantation · 2020
7. Early nerve fibre regeneration in individuals with type 1 diabetes after simultaneous pancreas and kidney transplantationDiabetologia · 2019
8. Corneal confocal microscopy: ready for prime timeClinical and Experimental Optometry · 2019
9. Corneal nerve fiber size adds utility to the diagnosis and assessment of therapeutic response in patients with small fiber neuropathyScientific Reports · 2018
10. Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitisScientific Reports · 2017
11. Quantification of small fiber pathology in patients with sarcoidosis and chronic pain using cornea confocal microscopy and skin biopsiesJournal of Pain Research · 2017
12. Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic PainInvestigative Ophthalmology & Visual Science · 2017
13. Targeting the innate repair receptor to treat neuropathyPAIN Reports · 2016
14. ARA290, a Specific Agonist of Erythropoietin/CD131 Heteroreceptor, Improves Circulating Endothelial Progenitors’ Angiogenic Potential and Homing AbilityShock · 2016
15. Cornea nerve fiber quantification and construction of phenotypes in patients with fibromyalgiaScientific Reports · 2016
16. An Engineered Innate Repair Receptor Agonist, ARA 290, Protects Rat Islets from Cytokine-induced ApoptosisJournal of Diabetes & Metabolism · 2016
17. A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted IsletsTransplantation · 2015
18. Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietinPharmacology & Therapeutics · 2015
19. ARA 290 for treatment of small fiber neuropathy in sarcoidosisExpert Opinion on Investigational Drugs · 2014
20. Discovery of a Master Regulator of Injury and Healing: Tipping the Outcome from Damage toward RepairMolecular Medicine · 2014